These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38561370)

  • 1. Effect of hydroxychloroquine blood concentration on the efficacy and ocular toxicity of systemic lupus erythematosus.
    Liu PC; Luo SL; Lv MN; Wang Y; Li JB; Yu SJ; Wu R
    Sci Rep; 2024 Apr; 14(1):7674. PubMed ID: 38561370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study.
    Fernandez-Ruiz R; Bornkamp N; Kim MY; Askanase A; Zezon A; Tseng CE; Belmont HM; Saxena A; Salmon JE; Lockshin M; Buyon JP; Izmirly PM
    Arthritis Res Ther; 2020 Aug; 22(1):191. PubMed ID: 32807233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of early retinal changes in patients on long-term hydroxychloroquine using optical coherence tomography angiography.
    Zhao H; Pan M; Liu Y; Cheng F; Shuai Z
    Ther Adv Drug Saf; 2024; 15():20420986231225851. PubMed ID: 38300766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The presumable effects of hydroxychloroquine and its metabolites in the treatment of systemic lupus erythematosus.
    Pan M; Jin R; Dai Y; Gao B; Liu Y; Peng X; Qiao J; Shuai Z
    Int Immunopharmacol; 2024 Jan; 126():111269. PubMed ID: 38006753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis.
    Lenfant T; Salah S; Leroux G; Bousquet E; Le Guern V; Chasset F; Francès C; Morel N; Chezel J; Papo T; Cacoub P; Mouthon L; Guettrot-Imbert G; Cohen P; Régent A; Mauget-Faÿsse M; Piette JC; Jallouli M; Costedoat-Chalumeau N;
    Rheumatology (Oxford); 2020 Dec; 59(12):3807-3816. PubMed ID: 32442312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered microvascular density in patients with systemic lupus erythematosus treated with hydroxychloroquine-an optical coherence tomography angiography study.
    Mihailovic N; Leclaire MD; Eter N; Brücher VC
    Graefes Arch Clin Exp Ophthalmol; 2020 Oct; 258(10):2263-2269. PubMed ID: 32533282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
    Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
    Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Related to Blood Hydroxychloroquine Concentration in Patients With Systemic Lupus Erythematosus.
    Yeon Lee J; Lee J; Ki Kwok S; Hyeon Ju J; Su Park K; Park SH
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):536-542. PubMed ID: 27390146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus.
    Miyagawa I; Nakano K; Nakayamada S; Iwata S; Hanami K; Fukuyo S; Kubo S; Kawabe A; Miyazaki Y; Inoue Y; Ueno M; Ohkubo N; Fujita Y; Tanaka Y
    Int J Rheum Dis; 2020 Apr; 23(4):549-558. PubMed ID: 32020727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of obesity on hydroxychloroquine blood levels in lupus nephritis patients.
    Pedrosa T; Kupa LVK; Pasoto SG; Aikawa NE; Borba EF; Duarte NJ; Leon EP; Silva CA; Bonfá E
    Lupus; 2021 Apr; 30(4):554-559. PubMed ID: 33402039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis.
    Mok CC; Penn HJ; Chan KL; Tse SM; Langman LJ; Jannetto PJ
    Arthritis Care Res (Hoboken); 2016 Sep; 68(9):1295-302. PubMed ID: 26749299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cumulative dose of hydroxychloroquine is associated with a decrease of resting heart rate in patients with systemic lupus erythematosus: a pilot study.
    Cairoli E; Danese N; Teliz M; Bruzzone MJ; Ferreira J; Rebella M; Cayota A
    Lupus; 2015 Oct; 24(11):1204-9. PubMed ID: 25852050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.
    Jallouli M; Francès C; Piette JC; Huong du LT; Moguelet P; Factor C; Zahr N; Miyara M; Saadoun D; Mathian A; Haroche J; De Gennes C; Leroux G; Chapelon C; Wechsler B; Cacoub P; Amoura Z; Costedoat-Chalumeau N;
    JAMA Dermatol; 2013 Aug; 149(8):935-40. PubMed ID: 23824340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
    Almeida-Brasil CC; Hanly JG; Urowitz M; Clarke AE; Ruiz-Irastorza G; Gordon C; Ramsey-Goldman R; Petri MA; Ginzler EM; Wallace DJ; Bae SC; Romero-Diaz J; Dooley MA; Peschken C; Isenberg D; Rahman A; Manzi S; Jacobsen S; Lim SS; van Vollenhoven R; Nived O; Jönsen A; Kamen DL; Aranow C; Sánchez-Guerrero J; Gladman DD; Fortin PR; Alarcon GS; Merrill JT; Kalunian K; Ramos-Casals M; Steinsson K; Zoma A; Askanase AD; Khamashta M; Bruce IN; Inanc M; Lukusa L; Bernatsky S
    Lupus Sci Med; 2022 Nov; 9(1):. PubMed ID: 36396267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features of ocular damage in systemic lupus erythematosus and risk factors for hydroxychloroquine-related complications.
    Cheng T; Gu X; Yang Z; Wang C; Chen Y; Zhao X
    Surv Ophthalmol; 2024; 69(5):733-742. PubMed ID: 38782129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus.
    Fasano S; Messiniti V; Iudici M; Coscia MA; Ciccia F
    Lupus Sci Med; 2023 Jan; 10(1):. PubMed ID: 36631164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort.
    Geraldino-Pardilla L; Perel-Winkler A; Miceli J; Neville K; Danias G; Nguyen S; Dervieux T; Kapoor T; Giles J; Askanase A
    Lupus; 2019 Jun; 28(7):862-867. PubMed ID: 31122136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus.
    Morita S; Takahashi T; Yoshida Y; Yokota N
    Ther Drug Monit; 2016 Apr; 38(2):259-67. PubMed ID: 26587870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of retinal changes measured by optical coherence tomography in the assessment of hydroxychloroquine ocular safety in patients with systemic lupus erythematosus.
    Martín-Iglesias D; Artaraz J; Fonollosa A; Ugarte A; Arteagabeitia A; Ruiz-Irastorza G
    Lupus; 2019 Apr; 28(4):555-559. PubMed ID: 30755141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose.
    Wakiya R; Kameda T; Nakashima S; Shimada H; Fahmy Mansour MM; Kato M; Miyagi T; Kadowaki N; Dobashi H
    Intern Med; 2020 Sep; 59(17):2105-2112. PubMed ID: 32522920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.